Anti-Human CD20 Reference Antibody (MT-3724, RUO) (HY257366)

Name: Anti-Human CD20 Reference Antibody (MT-3724, RUO)
Brand: abinScience
SKU: HY257366
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY257366
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
ID de clon	MT-3724
Actividad biológica	MT-3724 specifically targets and directly kills CD20 + cells via permanent ribosomal inactivation [1]. MT-3724‘s Shiga toxin A subunit inhibits protein synthesis and promotes apoptosis of tumor cells [2]. MT-3724 reduces tumor growth in a Daudi-Luc xenograft murine model of B-cell non-Hodgkin's lymphoma [1].
Objetivo	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P11836
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	MT-3724, MT3724, MT3724
Fondo	B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). 1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111 2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015 3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739 4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
Referencias	1. Hamlin PA, et al. Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. Cancer Res Commun. 2022;2(5):307-315. Published 2022 May 5. [HY257366] 2. Robinson GL, et al. Abstract 1483: MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin's lymphoma. Cancer Res. 2016;76(14_Supplement):1483. [HY257366]
Nota	For research use only. Not suitable for clinical or therapeutic use.